<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ritonavir</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00503</strong>&#160; (APRD00312)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>An <span class="caps">HIV</span> protease inhibitor that works by interfering with the reproductive cycle of <span class="caps">HIV</span>. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00503/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00503/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00503.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00503.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00503.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00503.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00503.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00503">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ritonavir</td><td>French/German/Spanish</td><td>INN</td></tr><tr><td>Ritonavirum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Busvir</td><td>Conifarma</td></tr><tr><td>Empetus</td><td>Emcure</td></tr><tr><td>Normune</td><td>Grey Inversiones</td></tr><tr><td>Norvir</td><td>AbbVie, Inc.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Kaletra</td><td>Lopinavir + Ritonavir</td></tr><tr><td>V-Letra</td><td>Lopinavir + Ritonavir</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>155213-67-5</td></tr><tr><th>Weight</th><td>Average: 720.944<br>Monoisotopic: 720.312760056</td></tr><tr><th>Chemical Formula</th><td>C<sub>37</sub>H<sub>48</sub>N<sub>6</sub>O<sub>5</sub>S<sub>2</sub></td></tr><tr><th>InChI Key</th><td>NCDNCNXCDXHOMX-XGKFQTDJSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[(2S)-3-methyl-2-{[methyl({[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl})carbamoyl]amino}butanamido]-1,6-diphenylhexan-2-yl]carbamate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>N-carbamoyl-alpha Amino Acids and Derivatives</td></tr><tr><th>Alternative parents</th><td>Alpha Amino Acid Amides; Amphetamines and Derivatives; 2,4-disubstituted Thiazoles; Tertiary Amines; Carbamic Acids and Derivatives; Secondary Carboxylic Acid Amides; Secondary Alcohols; Ethers; Carboxylic Acids; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>amphetamine or derivative; 2,4-disubstituted 1,3-thiazole; benzene; thiazole; azole; carboxamide group; tertiary amine; carbamic acid derivative; secondary carboxylic acid amide; secondary alcohol; ether; enolate; polyamine; carboxylic acid; amine; organonitrogen compound; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the n-carbamoyl-alpha amino acids and derivatives. These are compounds containing an alpha amino acid (or a derivative thereof) which bears an carbamoyl group at his terminal nitrogen atom.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Indicated in combination with other antiretroviral agents for the treatment of HIV-infection.</td></tr><tr><th>Pharmacodynamics</th><td>Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Ritonavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.</td></tr><tr><th>Mechanism of action</th><td>Ritonavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.</td></tr><tr><th>Absorption</th><td>The absolute bioavailability of ritonavir has not been determined.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>98-99%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Five metabolites have been identified. The isopropylthiazole oxidation metabolite (M-2) is the major metabolite and has antiviral activity similar to that of ritonavir, however, plasma concentrations are low. The cytochrome P450 enzymes CYP3A and CYP2D6 are primarily involved in the metabolism of ritonavir.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Ritonavir</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002363" target="_blank">Cytochrome P450 2D6</a></li></ul></td><td><a href="/metabolites/DBMET00084">N-Desmethylritonavir</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/84">Details</a></td></tr><tr><td>Ritonavir</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET00385">Hydroxy Ritonavir</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/387">Details</a></td></tr><tr><td>Ritonavir</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET01182">Ritonavir metabolite M1</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1326">Details</a></td></tr><tr><td>Ritonavir</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002362" target="_blank">Cytochrome P450 3A5</a></li></ul></td><td><a href="/metabolites/DBMET01183">Ritonavir metabolite M11</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1327">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>3-5 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Human experience of acute overdose with ritonavir is limited. One patient in clinical trials took ritonavir 1500 mg/day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose. The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice.</td></tr><tr><th>Affected organisms</th><td><ul><li>Human Immunodeficiency Virus</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.7195</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9717</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8957</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8307</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8317</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8753</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9009</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.694</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8918</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5973</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.67</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6229</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8424</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.5399</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.5843</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5946</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7378
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8664
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9633
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6154 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9774
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8457
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Abbott laboratories pharmaceutical products div</li>
<li>Abbott laboratories</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.abbott.com">Abbott Laboratories Ltd.</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.catalent.com">Catalent Pharma Solutions</a></li>
<li>DHHS Program Support Center Supply Service Center</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Solution</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01048">Abacavir</a></td><td>The serum concentration of Abacavir may be decreased by protease inhibitors such as Ritonavir. The antiviral response should be closely monitored.</td></tr><tr><td><a href="/drugs/DB05812">Abiraterone</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00346">Alfuzosin</a></td><td>Ritonavir increases the effect/toxicity of alfuzosin</td></tr><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, alprazolam.</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Ritonavir decreases the effect of theophylline</td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Ritonavir increases the effect and toxicity of amiodarone</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, amitriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ritonavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, amoxapine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amoxapine if ritonavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06605">Apixaban</a></td><td>Avoid combination. Otherwise, ritonavir will likely increase apixaban serum concentration.</td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>This CYP3A4 inhibitor increases the effect and toxicity of aprepitant</td></tr><tr><td><a href="/drugs/DB00637">Astemizole</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Association with dose adjustment</td></tr><tr><td><a href="/drugs/DB00289">Atomoxetine</a></td><td>The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Ritonavir may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if ritonavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06237">Avanafil</a></td><td>Co-administration with the strong CYP3A4 inhibitor ritonavir resulted in an approximate 13-fold increase in AUC0-inf and 2.4-fold increase in Cmax of avanafil. </td></tr><tr><td><a href="/drugs/DB01244">Bepridil</a></td><td>Ritonavir increases the effect and toxicity of bepridil</td></tr><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if ritonavir is initiated, discontinued or dose changed. Dosage adjustments may be required. </td></tr><tr><td><a href="/drugs/DB01156">Bupropion</a></td><td>Ritonavir increases the effect and toxicity of bupropion</td></tr><tr><td><a href="/drugs/DB00490">Buspirone</a></td><td>Ritonavir increases the effect and toxicity of buspirone</td></tr><tr><td><a href="/drugs/DB06772">Cabazitaxel</a></td><td>Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.</td></tr><tr><td><a href="/drugs/DB08907">Canagliflozin</a></td><td>Nonselective inducers of UGT enzymes may decrease levels of canagliflozin, thus decreasing efficacy. Consider increase the dose to 300 mg once daily. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Ritonavir increases the effect of carbamazepine</td></tr><tr><td><a href="/drugs/DB00475">Chlordiazepoxide</a></td><td>The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, chlordiazepoxide.</td></tr><tr><td><a href="/drugs/DB01410">Ciclesonide</a></td><td>Increased effects/toxicity of ciclesonide</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, clomipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of clomipramine if ritonavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01068">Clonazepam</a></td><td>The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, clonazepam.</td></tr><tr><td><a href="/drugs/DB00628">Clorazepate</a></td><td>The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, clorazepate.</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Ritonavir increases the effect and toxicity of clozapine</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>The protease inhibitor, ritonavir, may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB01219">Dantrolene</a></td><td>Ritonavir may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ritonavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00496">Darifenacin</a></td><td>This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Increases the effect of ritonavir</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, desipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of desipramine if ritonavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00647">Dextropropoxyphene</a></td><td>Ritonavir increases the levels of analgesic</td></tr><tr><td><a href="/drugs/DB00829">Diazepam</a></td><td>The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, diazepam.</td></tr><tr><td><a href="/drugs/DB00390">Digoxin</a></td><td>Ritonavir increases levels/effect of digoxin</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>The protease inhibitor, ritonavir, may increase the effect and toxicity of the ergot derivative, dihydroergotamine.</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Ritonavir increases diltiazem levels</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, doxepin, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxepin if ritonavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Ritonavir is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. </td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>The protease inhibitor, ritonavir, may increase the effect and toxicity of eletriptan.</td></tr><tr><td><a href="/drugs/DB00700">Eplerenone</a></td><td>This protease inhibitor, ritonavir, may increase the effect and toxicity of eplerenone.</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>The protease inhibitor, ritonavir, may increase the effect and toxicity of the ergot derivative, ergotamine.</td></tr><tr><td><a href="/drugs/DB00530">Erlotinib</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Increased toxicity of both agents</td></tr><tr><td><a href="/drugs/DB01215">Estazolam</a></td><td>The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, estazolam.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>Ritonavir could decrease the contraceptive efficacy</td></tr><tr><td><a href="/drugs/DB00813">Fentanyl</a></td><td>Ritonavir increases the effect and toxicity of fentanyl/alfentanyl</td></tr><tr><td><a href="/drugs/DB01195">Flecainide</a></td><td>Ritonavir increases the toxicity of the anti-arrhythmic</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Increased risk of serotonin syndrome</td></tr><tr><td><a href="/drugs/DB00690">Flurazepam</a></td><td>The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB08906">Fluticasone furoate</a></td><td>Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Consider alternative therapy. </td></tr><tr><td><a href="/drugs/DB02703">Fusidic Acid</a></td><td>The protease inhibitor, ritonavir, may increase the effect and toxicity of fusidic acid.</td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of gefitinib</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, imipramine, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ritonavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB05039">Indacaterol</a></td><td>Strong inhibitors of CYP3A4 may increase levels of indacaterol. Monitor closely for adverse events. </td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase the effect and toxicity of ritonavir.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may increase the effect and toxicity of ritonavir.</td></tr><tr><td><a href="/drugs/DB08882">Linagliptin</a></td><td>CYP3A4 inhibitors may increase levels of linagliptin. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Ritonavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00358">Mefloquine</a></td><td>Mefloquine decreases the effect of ritonavir</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>The protease inhibitor, ritonavir, may decrease the effect of methadone.</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Ritonavir may increase the effect and toxicity of the tricyclic antidepressant, nortriptyline, by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ritonavir if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00334">Olanzapine</a></td><td>Ritonavir decreases the effect of olanzapine</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Ritonavir decreases the effect of theophylline</td></tr><tr><td><a href="/drugs/DB06589">Pazopanib</a></td><td>Ritonavir is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib. </td></tr><tr><td><a href="/drugs/DB00454">Pethidine</a></td><td>Ritonavir increases the levels of analgesic</td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>The protease inhibitor, ritonavir, may increase the effect and toxicity of pimozide.</td></tr><tr><td><a href="/drugs/DB00554">Piroxicam</a></td><td>Ritonavir increases the toxicity of piroxicam</td></tr><tr><td><a href="/drugs/DB08901">Ponatinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB08901">Ponatinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB06209">Prasugrel</a></td><td>Ritonavir is a inhibitor of CYP3A4, thus blocking the bioactivation of prasugrel. As a result, a reduction in prasugrel efficiency may be observed in patients.  </td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Ritonavir increases the effect and toxicity of propafenone</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Ritonavir increases the effect and toxicity of quinidine</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Increased levels of ranolazine - risk of toxicity</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Rifabutin decreases the effect of ritonavir</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin decreases the effect of ritonavir</td></tr><tr><td><a href="/drugs/DB06228">Rivaroxaban</a></td><td>Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 like ritonavir and P-glycoproteins are contraindicated.</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Affects CYP1A2 metabolism; decreases level or effect of roflumilast. </td></tr><tr><td><a href="/drugs/DB06335">Saxagliptin</a></td><td>Ritonavir is an inhibitor of CYP3A4 which increases exposure of saxagliptin. Decrease dose of saxagliptin to 2.5 mg per day. </td></tr><tr><td><a href="/drugs/DB06207">Silodosin</a></td><td>Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated. </td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>The protease inhibitor, Ritonavir, may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ritonavir therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>Ritonavir may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Ritonavir may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Ritonavir, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ritonavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Ritonavir may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Ritonavir may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00444">Teniposide</a></td><td>The strong CYP3A4 inhibitor, Ritonavir, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ritonavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Ritonavir decreases the effect of theophylline</td></tr><tr><td><a href="/drugs/DB00906">Tiagabine</a></td><td>The strong CYP3A4 inhibitor, Ritonavir, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ritonavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Ritonavir may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB06212">Tolvaptan</a></td><td>Ritonavir is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan. </td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Ritonavir, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Ritonavir may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ritonavir may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The protease inhibitor, Ritonavir, may increase the efficacy/toxicity of Trazodone by inhibiting Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Ritonavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00755">Tretinoin</a></td><td>The strong CYP2C8 inhibitor, Ritonavir, may decrease the metabolism and clearance of oral Tretinoin. Consider alternate therapy or monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Ritonavir is initiated, discontinued to dose changed. </td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>The protease inhibitor, ritonavir, may increase the effect of the benzodiazepine, triazolam.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The strong CYP3A4/CYP2D6 inhibitor, Ritonavir, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2D6 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ritonavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00862">Vardenafil</a></td><td>Ritonavir, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB08881">Vemurafenib</a></td><td>Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Ritonavir, a CYP2D6 and CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP2D6 and CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ritonavir is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ritonavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>Ritonavir, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ritonavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00541">Vincristine</a></td><td>Ritonavir, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ritonavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00361">Vinorelbine</a></td><td>Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ritonavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Ritonavir may decrease the serum concentration of voriconazole by increasing its metabolism. Concomitant therapy with high dose ritonavir is contraindicated. Caution should be used with lower doses as decreased voriconazole efficacy may occur. </td></tr><tr><td><a href="/drugs/DB00425">Zolpidem</a></td><td>Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ritonavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00909">Zonisamide</a></td><td>Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ritonavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01198">Zopiclone</a></td><td>Ritonavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ritonavir is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Ritonavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if ritonavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Ritonavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if ritonavir is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Ritonavir, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if ritonavir is initiated, discontinued or dose changed. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid St.John's Wort.</li>
<li>Take with food.</li></ul></td></tr></tbody></table>